MONMOUTH JUNCTION, N.J., Nov. 13, 2006 (PRIMEZONE) -- MedaSorb Technologies Corporation (OTCBB:MSBT) announced today that it has filed a new patent application covering its Ultra Select(tm) polymer technology. This new technology extends MedaSorb's line of products that are in the process of commercialization. The polymer is being developed for use with medical applications requiring long term use and extended treatment times, such as nightly dialysis. MedaSorb believes that its Ultra Select(tm) polymer is highly selective in extracting only midsize proteins, such as cytokines and B2-microglobulin, from blood and other physiologic fluids, while keeping the components required for good health such as cells, platelets, albumin, hemoglobin, fibrinogen, and other serum proteins intact. This patent application, once approved, will further strengthen MedaSorb's intellectual property portfolio.
Al Kraus the CEO of MedaSorb said, "MedaSorb is excited to complete this important new patent application. We believe our next generation products will benefit from this new selective polymer. We expect to use Ultra Select(tm) as an addition to our BetaSorb(tm) line of products, to provide enhanced treatment options for end stage renal patients. Additionally, we continue to focus on the upcoming FDA filings for our CytoSorb(tm) product for both the sepsis and drug detoxicification indications."
About MedaSorb
MedaSorb Technologies Corporation is a medical device company headquartered in Monmouth Junction, New Jersey. MedaSorb is a development stage company that has developed and is preparing to commercialize a blood purification technology that efficiently removes toxic compounds from circulating blood.
MedaSorb's initial products (CytoSorb(tm) and BetaSorb(tm)), are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. MedaSorb believes that potential healthcare applications for its products include: adjunctive treatment and/or prevention of sepsis; prevention of damage to organs donated for transplant prior to organ harvest; prevention of post-operative complications of cardiac surgery; short and long-term treatment of kidney failure; and drug detoxification.
MedaSorb's management team is led by Al Kraus, President and CEO, who has more than twenty-five years' experience managing companies in the dialysis, medical device products, personal computer and custom software industries. Other members of MedaSorb's management team include James Winchester, MD, CMO, Vincent Capponi, COO, and David Lamadrid, CFO.
Forward Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation believes that its primary risk factors include, but are not limited to: ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; obtaining government approvals, including required FDA approvals; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Current Report on Form 8-K filed with the SEC on July 6, 2006, which is available at www.sec.gov